Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 4/20 | 0.71 |
| ▸ | PDGFRA | P16234 | 10/20 | 0.67 |
| ▸ | KDR | P35968 | 7/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.67 |
| ▸ | KIT | P10721 | 2/20 | 0.64 |
| ▸ | FLT3 | P36888 | 1/20 | 0.61 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.61 |
| ▸ | MET | P08581 | 1/20 | 0.61 |
| ▸ | AXL | P30530 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7486104 | 0.90 | AXL (0.73) | PDGFRAKDRKITFLT3AURKB | |
| SCHEMBL7487378 | 0.89 | FGFR2 (0.77) | FGFR2PDGFRAKDRPDGFRBKIT | |
| SCHEMBL23922789 | 0.88 | FGFR2 (0.69) | FGFR2PDGFRAKDRPDGFRBKIT | |
| SCHEMBL3794599 | 0.88 | FGFR2 (0.69) | FGFR2PDGFRAKDRPDGFRBKIT | |
| SCHEMBL2747572 | 0.88 | PDGFRA (0.62) | FGFR2PDGFRAKDRPDGFRBKIT | |
| SCHEMBL29262927 | 0.87 | MET (0.58) | FGFR2PDGFRAKDRKITAURKB | |
| SCHEMBL22972142 | 0.86 | EGFR (0.66) | PDGFRAKDRPDGFRBKITAURKB | |
| SCHEMBL7481918 | 0.86 | FGFR2 (0.77) | FGFR2PDGFRAKDRPDGFRBMET | |
| SCHEMBL7482945 | 0.86 | FGFR2 (0.72) | FGFR2PDGFRAKDRPDGFRBKIT | |
| SCHEMBL7482620 | 0.85 | FGFR2 (0.76) | FGFR2PDGFRAKDRPDGFRBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116763787-A | New application of quinoline compound | 安徽中科拓苒药物科学研究有限公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2023168740-A1 | NOVEL USE OF QUINOLINE COMPOUND | 安徽中科拓苒药物科学研究有限公司 | 2023-09-14 | — | — | WO | disclosed |
| CN-111303024-B | Quinoline-structured pan-KIT kinase inhibitor and application thereof | 安徽中科拓苒药物科学研究有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20220064117-A1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | Tarapeutics Science Inc. (CN) | 2022-03-03 | — | — | US | disclosed |
| CN-111303024-A | Quinoline-structured pan-KIT kinase inhibitor and application thereof | 安徽中科拓苒药物科学研究有限公司 | 2020-06-19 | — | — | CN | disclosed |
| WO-2020118753-A1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | 安徽中科拓苒药物科学研究有限公司 | 2020-06-18 | — | — | WO | disclosed |
| EP-0860433-B1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF GROWTH FACTOR RECEPTOR ORIGINATING IN PLATELET AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KIRIN BREWERY (JP) | 2002-07-03 | — | — | EP | disclosed |
| US-6143764-A | ETHER DERIVATIVES OF QUINOLINE, ANTITUMOR AGENTS | KIRIN BEER KABUSHIKI KAISHA (JP) | 2000-11-07 | — | — | US | disclosed |
| EP-0860433-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF GROWTH FACTOR RECEPTOR ORIGINATING IN PLATELET AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 1998-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064117-A1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | KIT, MAP3K7, ABL1 | FGFR2 1630/4885PDGFRA 747/4885KDR 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.